Relmada Therapeutics Inc (RLMD)
NASDAQ
News
Market Data
Register for real-time alerts, custom portfolio, and market movers
The current RLMD market cap is 11.15M. The company's latest EPS is USD -3.2741 and P/E is -0.11.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -22.69M | -26.83M | -22.99M | -18.82M | -23.01M |
| Net Income | -22M | -25.17M | -21.83M | -17.77M | -21.73M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -8.27M | -60.84M | -125.7M | -161.25M | -103.7M |
| Net Income | -8.2M | -59.46M | -125.75M | -157.04M | -98.79M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 109.15M | 97.55M | 84.41M | 71.03M | 55.73M |
| Total Liabilities | 8.42M | 12.2M | 12.36M | 9.54M | 8.1M |
| Total Equity | 100.73M | 85.36M | 72.05M | 61.49M | 47.63M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 117.14M | 118.19M | 223.33M | 152.91M | 97.55M |
| Total Liabilities | 1.46M | 12.6M | 15.06M | 12.47M | 12.2M |
| Total Equity | 115.68M | 105.58M | 208.27M | 140.44M | 85.36M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -41.41M | -51.66M | -13.04M | -26.3M | -42.96M |
| Investing | 42.71M | 50.45M | 10.06M | 24.07M | 40.22M |
| Financing | N/A | -98k | 222k | 222k | 132k |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -6.41M | -27.81M | -91.87M | -103.8M | -51.66M |
| Investing | -80.17M | -34.45M | -54.12M | 19.73M | 50.45M |
| Financing | 113.64M | 28.47M | 187.94M | 45.02M | -98k |
| Market Cap | 11.15M |
| Price to Earnings Ratio | -0.11 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 2.65 |
| Price to Book Ratio | 0.13 |
| Dividend Yield | - |
| Shares Outstanding | 30.17M |
| Average Volume (1 week) | 552.26k |
| Average Volume (1 Month) | 2.37M |
| 52 Week Change | -87.89% |
| 52 Week High | 7.2225 |
| 52 Week Low | 0.3416 |
| Spread (Intraday) | 0.02 (5.01%) |
| Company Name | Relmada Therapeutics Inc |
| Address |
50 west liberty street suite 880 reno, nevada 89501 |
| Website | https://www.relmada.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
